Drug Profile
Research programme: anti-G protein-coupled receptor antibodies - Omeros
Latest Information Update: 24 Mar 2023
Price :
$50
*
At a glance
- Originator Omeros Corporation
- Class Antibodies
- Mechanism of Action G protein-coupled receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 15 Feb 2023 Omeros Corporation has multiple patent protection related to anti-G protein-coupled receptor antibodies in USA and world-wide before February 2023
- 15 Feb 2023 Omeros Corporation has multiple patents pending related to anti-G protein-coupled receptor antibodies in USA and world-wide before February 2023
- 28 Jul 2018 No recent reports of development identified for preclinical development in Neurological-disorders in USA (Parenteral)